Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.

Michel Delforge,Paula Rodríguez Otero,Nina Shah,Olga Moshkovich,Julia Braverman,Devender S Dhanda,Sally Lanar,Jennifer Devlen,Matthew Miera,Heather Gerould,Timothy B Campbell,Nikhil C Munshi

Leukemia research（2023）

引用 0|浏览24

暂无评分

摘要

Longitudinal analysis of patient experiences showed sustained benefits and preference for ide-cel up to 24 months after treatment. Trial Registration Number and Date: NCT03361748. December 5, 2017.

查看译文

关键词

CAR T cell therapy,Idecabtagene vicleucel,Patient experience,Patient-reported outcomes,Relapsed or refractory multiple myeloma,Triple-class exposed

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要